Nektar Dodges Stock-Drop Suit Over Poor Study Results
A California federal judge has dismissed a stock-drop proposed class action against biopharmaceutical research company Nektar, saying investors hadn't provided specific details in their allegations that the company misled them about...To view the full article, register now.
Already a subscriber? Click here to view full article